Latest Biotechnology News

Page 51 of 57
Biotron Limited reported a robust net cash inflow of $1.095 million for the December 2024 quarter, driven largely by government grants, supporting its operational stability despite ongoing R&D expenses.
Ada Torres
Ada Torres
3 Feb 2025
Medlab Clinical reports a near-empty cash balance and zero receipts in Q2 2025, while actively pursuing a business acquisition ahead of its ASX removal date.
Ada Torres
Ada Torres
3 Feb 2025
Alterity Therapeutics has raised over A$2 million through its U.S. ATM facility and expects nearly A$5.7 million in Australian tax rebates, fueling the advancement of its lead neurodegenerative drug candidate ATH434 following promising Phase 2 results.
Ada Torres
Ada Torres
3 Feb 2025
Argent BioPharma reports strategic cost-cutting moves including facility closures and delisting from the LSE, while securing German distribution approval and raising significant capital to support its drug pipeline.
Ada Torres
Ada Torres
31 Jan 2025
Skin Elements Limited reports steady progress in commercialising its plant-based SE Formula biotechnology, highlighted by ongoing product trials, a successful R&D rebate, and a $513k non-renounceable entitlement issue.
Ada Torres
Ada Torres
31 Jan 2025
BPH Global Limited secured $325,000 in funding during the December quarter, progressing its Indonesian seaweed venture and renewing key R&D partnerships. The company ends the quarter with $226,000 cash on hand and plans a $1 million capital raise at an upcoming EGM.
Ada Torres
Ada Torres
31 Jan 2025
Hexima Limited has called off its planned acquisition of AI developer Real Thing Entertainment, ending the quarter with $1.64 million in cash and a cautious outlook on future strategic moves.
Ada Torres
Ada Torres
31 Jan 2025
Paradigm Biopharmaceuticals has launched a Loyalty and Piggyback Options program aimed at rewarding shareholders and raising up to $111.96 million to support its pivotal Phase III clinical trial.
Victor Sage
Victor Sage
31 Jan 2025
Prescient Therapeutics has secured FDA clearance for its PTX-100 Phase 2 trial targeting relapsed/refractory cutaneous T-cell lymphoma, while also appointing James McDonnell as its new CEO. The company reports steady progress in its cell therapy platforms and maintains a solid cash position bolstered by a recent R&D tax rebate.
Ada Torres
Ada Torres
31 Jan 2025
Cambium Bio has secured a A$3 million capital raise and achieved FDA Fast Track status for its lead ophthalmology product, Elate Ocular®, setting the stage for Phase 3 trials in mid-2025.
Ada Torres
Ada Torres
31 Jan 2025
Tissue Repair Limited reports initial patient enrolment in its pivotal Phase 3 trial for TR987®, alongside a robust 35% quarterly sales increase for its TR Pro+® product. The company is also advancing manufacturing and distribution strategies to support growth.
Ada Torres
Ada Torres
31 Jan 2025
Papyrus Australia Ltd reported a $284,000 net cash outflow for the December 2024 quarter, reflecting abnormal expenses but maintaining a solid funding runway through existing facilities and strategic initiatives.
Victor Sage
Victor Sage
31 Jan 2025